Chemomab Therapeutics (CMMB) Tops Q4 EPS by 3c

Chemomab Therapeutics (NASDAQ: CMMB) reported Q4 EPS of $0.01, $0.03 better than the analyst estimate of ($0.02).

For earnings history and earnings-related data on Chemomab Therapeutics (CMMB) click here.

You May Also Be Interested In

• Micron offers Taiwan workers up to 68-month bonuses as strike threat looms
• Brinker Int'l (EAT) PT Lowered to $240 at DA Davidson Ahead of Analyst Day
• GE Vernova (GEV) PT Raised to $1,185 at Jefferies